Myelodysplastic Syndrome | Norton Healthcare

Indication: Myelodysplastic Syndrome

A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453
for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R,
or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Novartis Pharmaceuticals Corp

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.